Table 1 Estimated joinpoints and estimated regression coefficients of joinpoints regression during pre-vaccination and vaccination period
Vaccination phase | Joinpoint | Estimated joinpoints (days) | 95% confidence limits | Regression coefficients | Parameter estimation (S.E) | P-value | |
|---|---|---|---|---|---|---|---|
Lower | Upper | ||||||
Pre-vaccination (n = 303) 19/03/2020 to 15/01/2021 | 1 | 50 (7/5/2020) | 24 (11/4/2020) | 135 (31/7/2020) | Intercept 1 | 5.03 (0.32) | < 0.001 |
2 | 133 (29/7/2020) | 127 (23/7/2020) | 184 (18/9/2020) | Intercept 2 | 6.54 (0.09) | < 0.001 | |
3 | 182 (16/9/2020) | 179 (13/9/2020) | 273 (16/12/2020) | Intercept 3 | 9.12 (0.12) | < 0.001 | |
Intercept 4 | 14.03 (0.06) | < 0.001 | |||||
Slope 1 | 0.06 (0.01) | < 0.001 | |||||
Slope 2 | 0.03 (0.001) | < 0.001 | |||||
Slope 3 | 0.01 (0.001) | < 0.001 | |||||
Slope 4 | − 0.01 (0.0002) | < 0.001 | |||||
Slope 2–Slope 1 | − 0.03 (0.009) | < 0.001 | |||||
Slope 3–Slope 2 | − 0.02 (0.001) | < 0.001 | |||||
Slope 4–Slope 3 | − 0.03 (0.001) | < 0.001 | |||||
During vaccination (n = 715) 16/01/2021 to 31/12/2022 | 1 | 407 (29/4/2021) | 403 (25/4/2021) | 410 (2/5/2021) | Intercept 1 | − 5.44 (0.68) | < 0.001 |
2 | 643 (21/12/2021) | 635 (13/12/2021) | 650 (28/12/2021) | Intercept 2 | 20.80 (0.22) | < 0.001 | |
3 | 665 (12/1/2022) | 661 (8/1/2022) | 668 (15/1/2022) | Intercept 3 | − 117.36 (18.28) | < 0.001 | |
Intercept 4 | 23.41 (0.35) | < 0.001 | |||||
Slope 1 | 0.04 (0.002) | < 0.001 | |||||
Slope 2 | − 0.02 (0.0005) | < 0.001 | |||||
Slope 3 | 0.19 (0.03) | < 0.001 | |||||
Slope 4 | − 0.02 (0.0005) | < 0.001 | |||||
Slope 2–Slope 1 | − 0.06 (0.002) | < 0.001 | |||||
Slope 3–Slope 2 | 0.21 (0.03) | < 0.001 | |||||
Slope 4–Slope 3 | − 0.21 (0.03) | < 0.001 | |||||